Condition: Autoimmune Hemolytic Anemia · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
This description comes directly from the study's public registry record.
Paola Fazi · 0670390528 · p.fazi@gimema.it
Enrico Crea · 0670390514 · e.crea@gimema.it
Always discuss trial participation with your own doctor first.
| Ematologia Osp Careggi | Florence, Italy | Recruiting |
| Ematologia Osp Maggiore della Carità | Novara, Italy | Recruiting |
| Ematologia Osp Molinette | Torino, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05694312